Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells-Reference-Cited by-同舟云学术

Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells

Published:2015-01 Issue:1 Volume:32 Page:180-190
ISSN:1871-6784
Container-title:New Biotechnology
language:en
Short-container-title:New Biotechnology

Author:

Mittra J.,Tait J.,Mastroeni M.,Turner M.L.,Mountford J.C.,Bruce K.

Publisher

Elsevier BV

Subject

Molecular Biology,General Medicine,Bioengineering,Biotechnology

Reference46 articles.

1. Assessing the value of autologous and allogeneic cells for regenerative medicine;Mason;Regen Med,2009

2. Methodology for the analysis of life science innovation systems (ALSIS) and its application to three case studies;Mastroeni,2012

3. Speculative stem cell futures: some prospective commercial models for induced pluripotent stem (ips) cell based technologies;Harvey;J Fut Stud,2010

4. The promise of stem cells: a venture capital perspective;Prescott,2008

5. Regenerative Medicine Report;HOL,2013

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Constructing appropriate bioprinting regulations: the ethical importance of recognising a liminal technology;Journal of Medical Ethics;2023-07-14

2. The EHA Research Roadmap: Transfusion Medicine;HemaSphere;2022-01-25

3. Policy support for disruptive innovation in the life sciences;Technology Analysis & Strategic Management;2019-06-17

4. Beyond the limits to governance: New rules of engagement for the tentative governance of the life sciences;Research Policy;2019-06

5. ‘Synthetic Blood’: Entangling Politics and Biology;Body & Society;2019-01-14